Article (Scientific journals)
Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
Hubaux, Roland; Vandermeers, Fabian; Cosse, Jean-Philippe et al.
2015In ERJ Open Research, 1 (2), p. 00028
Peer Reviewed verified by ORBi


Full Text
Hubaux SCLC 2015.pdf
Publisher postprint (761.76 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to


Abstract :
[en] With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve secondline therapy of SCLC. The effect of chemotherapeutic agents was evaluated in cell lines (apoptosis, reactive oxygen species, and RNA and protein expression) and in mouse models (tumour development). We demonstrate here that valproic acid, a histone deacetylase inhibitor, improves the efficacy of a second-line regimen (vindesine, doxorubicin and cyclophosphamide) in SCLC cells and in mouse models. Transcriptomic profiling integrating microRNA and mRNA data identifies key signalling pathways in the response of SCLC cells to valproic acid, opening new prospects for improved therapies.
Disciplines :
Author, co-author :
Hubaux, Roland 
Vandermeers, Fabian 
Cosse, Jean-Philippe 
Crisanti, Cecilia
Kapoor, Veena
Albelda, Steven M.
Mascaux, Céline
Delvenne, Philippe 
Hubert, Pascale  
Willems, Luc  ;  Université de Liège > Agronomie, Bio-ingénierie et Chimie (AgroBioChem) > Biologie cell. et moléc.
Language :
Title :
Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
Publication date :
19 October 2015
Journal title :
ERJ Open Research
Publisher :
European Respiratory Society, Sheffield, United Kingdom
Volume :
Issue :
Pages :
Peer reviewed :
Peer Reviewed verified by ORBi
Name of the research project :
The Interuniversity Attraction Poles programme BELVIR initiated by the Belgian Science Policy Office
The Action de Recherche Concertée Glyvir of the Communauté française de Belgique
The Plan Cancer of the Service Public Fédéral
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Télévie [BE]
BELSPO - Belgian Science Policy Office [BE]
CFB - Communauté française de Belgique [BE]
Belgian Foundation Against Cancer [BE]
NEDO - New Energy and Industrial Technology Development Organization [JP]
SPW DGO6 - Service Public de Wallonie. Economie, Emploi, Recherche [BE]
CAC - Centre anticancéreux près l'Université de Liège asbl [BE]
ULiège. GxABT - Liège Université. Gembloux Agro-Bio Tech [BE]
ULg FSR - Université de Liège. Fonds spéciaux pour la recherche [BE]
Funding text :
The Partenariat Public Privé INCA of the Direction générale des Technologies, de la Recherche et de l’Energie/DG06 of the Walloon government
Available on ORBi :
since 12 January 2016


Number of views
37 (2 by ULiège)
Number of downloads
3 (3 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi